FDA Accepts Acromegaly Drug Filing From Ipsen
Posted on: Monday, 15 January 2007, 12:00 CST
Ipsen has said that the FDA has accepted the filing of its new drug application for Somatuline Autogel as a 28-day sustained-release formulation to treat patients with acromegaly.
This acceptance signifies the start of the review process of the new drug application with a "prescription drug user fee act" goal date set for 30 August 2007. Subject to the approval of the drug by the FDA, Ipsen's partner Tercica will market Somatuline Autogel in the US.
Somatuline Autogel has already received a marketing approval in Canada on 17 July 2006, and is currently being launched by Tercica under its distribution license agreement with Ipsen.
Somatuline was initially developed and continues to be used in the treatment of acromegaly, a disorder caused by the over-production of growth hormone secondary to a benign tumor of the anterior pituitary gland. The drug is also approved, outside of North America, for the treatment of symptoms associated with neuroendocrine tumors.
Source: Datamonitor
Related Articles
- Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials
- Ipsen and Spirogen Report Positive Results From Phase I Study of Antitumor Drug
- Biotech Industry Comes of Age
- Ipsen Submits BLA for Neuromotor Drug
- Ipsen: Somatuline(R) Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly
- Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing By FDA
- FDA Accepts for Filing a New Drug Application (NDA) for Somatuline(R) Autogel(R)
- 'Unshackled' Medicis on the Hunt: Scottsdale Company Eyes Rights to Botox-Like Drug
- Treatment With ^Sup 177^Lu-DOTATOC of Patients With Relapse of Neuroendocrine Tumors After Treatment With ^Sup 90^Y-DOTATOC
 |
 |
User Comments (0)
RSS Feeds